Volume 19, Issue 70 (May 2009)
J Mazandaran Univ Med Sci 2009, 19(70): 49-53 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kazemi Arababadi M, Mirzaei M, Rezazadeh Zarandi E, Hassanshahi G, Vatani Baf M. Evaluation of prevalence of d 32 mutation in CCR5 gene in breast cancer patients in Rafsanjan city. J Mazandaran Univ Med Sci 2009; 19 (70) :49-53
URL: http://jmums.mazums.ac.ir/article-1-549-en.html
URL: http://jmums.mazums.ac.ir/article-1-549-en.html
Abstract: (11016 Views)
Background and purpose: Chemokines and their receptors are expressed in different types of malignancies. CC chemokines MIP-1a (CCL3), MIP-1b (CCL4) and RANTES (CCL5) is believed to be anti-tumor and also aid to the metastasis in tumor microenvironment. CCR2 and CCR5 are special G-protein receptors for these chemokines. Due to the important role of CCR5 chemokine receptor in tumor biology, this project is designed to examine d 32 mutation in CCR5 gene regards breast cancer.
Materials and methods: This experimental study was performed during 2007-8 on 100 healthy adults and 36 breast cancer patients by Gap-PCR. The demographic information also was collected by questionner and t-test Chi-square was used for statistical analysis of data.
Results: Our results showed that none of breast cancer patients had CCR5-d 32 mutation while 3 (3%) cases of controls had heterozygotic form of this mutation.
Conclusion: Our results showed that there is not any CCR5-d 32 mutation in patients. Therefore, it appears that this mutation don’t play any role in breast cancer.
Materials and methods: This experimental study was performed during 2007-8 on 100 healthy adults and 36 breast cancer patients by Gap-PCR. The demographic information also was collected by questionner and t-test Chi-square was used for statistical analysis of data.
Results: Our results showed that none of breast cancer patients had CCR5-d 32 mutation while 3 (3%) cases of controls had heterozygotic form of this mutation.
Conclusion: Our results showed that there is not any CCR5-d 32 mutation in patients. Therefore, it appears that this mutation don’t play any role in breast cancer.
Type of Study: Research(Original) |
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s). Owned by Mazandaran University of Medical Sciences.
Contact Us
Address: Journal Office, Building No. 2, Mazandaran University of Medical Sciences, Moallem Square, Sari.Tel: +98 (011)34484874 Postal code: 48175-866 E-Mail: jmums@mazums.ac.ir Telefax: +98 (011)33262679
